- Home
- GIGM vs LIXT Comparison
GIGM vs LIXT Comparison
Compare GIGM & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- LIXT
- Stock Information
- Founded
- GIGM 1998
- LIXT 2005
- Country
- GIGM Taiwan
- LIXT United States
- Employees
- GIGM N/A
- LIXT N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- LIXT Health Care
- Exchange
- GIGM Nasdaq
- LIXT Nasdaq
- Market Cap
- GIGM 17.8M
- LIXT 20.5M
- IPO Year
- GIGM 2000
- LIXT N/A
- Fundamental
- Price
- GIGM $1.58
- LIXT $4.79
- Analyst Decision
- GIGM
- LIXT
- Analyst Count
- GIGM 0
- LIXT 0
- Target Price
- GIGM N/A
- LIXT N/A
- AVG Volume (30 Days)
- GIGM 6.8K
- LIXT 87.6K
- Earning Date
- GIGM 10-30-2025
- LIXT 11-07-2025
- Dividend Yield
- GIGM N/A
- LIXT N/A
- EPS Growth
- GIGM N/A
- LIXT N/A
- EPS
- GIGM N/A
- LIXT N/A
- Revenue
- GIGM $3,397,000.00
- LIXT N/A
- Revenue This Year
- GIGM N/A
- LIXT N/A
- Revenue Next Year
- GIGM N/A
- LIXT N/A
- P/E Ratio
- GIGM N/A
- LIXT N/A
- Revenue Growth
- GIGM 10.11
- LIXT N/A
- 52 Week Low
- GIGM $1.38
- LIXT $0.64
- 52 Week High
- GIGM $1.89
- LIXT $6.26
- Technical
- Relative Strength Index (RSI)
- GIGM 39.01
- LIXT 58.04
- Support Level
- GIGM $1.58
- LIXT $4.20
- Resistance Level
- GIGM $1.66
- LIXT $4.45
- Average True Range (ATR)
- GIGM 0.04
- LIXT 0.33
- MACD
- GIGM -0.01
- LIXT 0.05
- Stochastic Oscillator
- GIGM 21.41
- LIXT 87.50
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.